Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Fineline Cube Jul 1, 2026
Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Fineline Cube Jul 1, 2026
Company

Shanghai Henlius Biotech Reports 9.8% YOY Revenue Growth and Continued Profitability in 2024H1 Financial Report

Fineline Cube Aug 27, 2024

Shanghai Henlius Biotech Inc., a biopharmaceutical company based in China and listed on the Hong...

Company Drug

Changchun High & New Technology Industries Receives FDA Approval for GenSci098 Clinical Trial in Thyroid Eye Disease

Fineline Cube Aug 27, 2024

Changchun High & New Technology Industries (Group) Inc., a Chinese corporation listed on the Shenzhen...

Company Drug

Diversifying HPV Protection: Beijing Wantai’s Vaccine Filing Competes with Gardasil 9 in China

Fineline Cube Aug 27, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai...

Company Drug

BeiGene Advances R/R CLL/SLL Treatment with FDA Fast-Tracked BGB-16673 in Phase I/II Clinical Trial

Fineline Cube Aug 27, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company, has been granted Fast...

Company

MicroPort Endovascular MedTech Reports 26.63% YOY Revenue Growth and Strong R&D Investment in 2024H1

Fineline Cube Aug 27, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese endovascular device manufacturer, has reported...

Company

Shanghai Pharmaceuticals Posts 5.14% YOY Revenue Growth in 2024H1 with Focus on Cell Therapies

Fineline Cube Aug 27, 2024

Shanghai Pharmaceuticals Holding Co. (SPH; HKG: 2607; SHA: 601607) has announced its financial results for...

Company

Innovent Biologics’ President Liu Yongjun Resigns, CEO De-Chao Micheal Yu Takes R&D Reins

Fineline Cube Aug 27, 2024

Innovent Biologics Inc., a leading biopharmaceutical company based in China and listed on the Hong...

Company Deals

Fosun Pharma’s Privatization of Henlius Includes Cash and Share Offers, Aims for Full Equity Control

Fineline Cube Aug 26, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and...

Company Drug

China’s CDE Approves Multitude Therapeutics’ AMT-676 for Clinical Study in Solid Tumors

Fineline Cube Aug 26, 2024

The Center for Drug Evaluation (CDE) of China has granted clinical study approval for Multitude...

Company Medical Device

Chinese NMPA Grants License to MicroPort Endovascular MedTech’s Venous Stent for Treating Vascular Conditions

Fineline Cube Aug 26, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd, a Chinese endovascular device manufacturer listed on the Shanghai...

Company Drug

Mabwell Bioscience Initiates Phase III Trial for 9MW2821 Combo in Urothelial Carcinoma Following NMPA Clearance

Fineline Cube Aug 26, 2024

Mabwell (Shanghai) Bioscience Co., Ltd, a biopharmaceutical company listed in China (SHA: 688062), has announced...

Company

CStone Pharmaceuticals Reports 2024 Interim Results with Strategic Collaborations and Regulatory Milestones

Fineline Cube Aug 26, 2024

CStone Pharmaceuticals, a biopharmaceutical company based in China and listed on the Hong Kong Stock...

Company Deals Medical Device

Suzhou-Based Medical Device Innovator Ensurge Secures RMB 100 Million in Latest Financing Round

Fineline Cube Aug 26, 2024

Ensurge, a cutting-edge medical device manufacturer headquartered in Suzhou, is reportedly in the spotlight for...

Company Drug

US FDA Approves Updated COVID-19 mRNA Vaccines from Pfizer/BioNTech and Moderna Ahead of Winter

Fineline Cube Aug 26, 2024

The U.S. Food and Drug Administration (FDA) has granted approval to two updated mRNA COVID-19...

Company

Guangzhou-Based Bio-Thera Solutions Expands Market Presence with Biosimilars and Innovative Drug Approvals

Fineline Cube Aug 26, 2024

Bio-Thera Solutions, a biotech company based in Guangzhou and listed on the Shanghai Stock Exchange...

Company Medical Device

National Healthcare Security Administration Reports Pricing Revisions on Aortic Stent Grafts by Major Manufacturers

Fineline Cube Aug 26, 2024

The National Healthcare Security Administration (NHSA) has reported that 12 device manufacturers, both domestic and...

Company Drug

Shouyao Holdings Receives Clinical Trial Approval for SY-7166 in Treating Multiple Myeloma

Fineline Cube Aug 26, 2024

Shouyao Holdings (Beijing) Co., Ltd, a biopharmaceutical company headquartered in Beijing and listed on the...

Company Drug

Takeda Prepares to File Dengue Fever Vaccine for US Approval, Expanding Global Regulatory Reach

Fineline Cube Aug 26, 2024

Takeda Pharmaceutical, a leading Japanese pharmaceutical company listed on the NYSE (NYSE: TAK), is reportedly...

Policy / Regulatory

China to Enhance Basic Medical Insurance Coverage for Residents in 2024 with Increased Subsidies and Personal Payments

Fineline Cube Aug 26, 2024

The National Healthcare Security Administration (NHSA), in conjunction with the Ministry of Finance and State...

Company Drug

Henlius Biotech’s Biosimilar Herceptin Approved by Health Canada for Breast and Gastric Cancer Treatments

Fineline Cube Aug 23, 2024

Shanghai Henlius Biotech Inc., a leading biopharmaceutical company based in China and listed on the...

Posts pagination

1 … 331 332 333 … 689

Recent updates

  • Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification
  • Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication
  • Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence
  • RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development
  • CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Company Drug

Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.